3 Pyschedelic Stocks That Investors Should Keep on Their Radars

: ATAI | ATAI Life Sciences N.V. News, Ratings, and Charts

ATAI – ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential.

Norms and regulations in society can change in the span of a few generations. We’ve lived through this with the rise of the cannabis industry. A few decades ago, most people were against its use for recreational and medicinal purposes. Today, medical marijuana has nearly unanimous approval, while a majority are in favor of its legalization for recreational use. 

We may be now going through the same process with psychedelic drugs such as LSD, psilocybin, and MDMA. There has been promising research and evidence that these substances can help with mental illnesses and anxiety in a much more effective way than traditional treatments with fewer side effects. Further, psychedelics have the power to help at a much more root-cause level than merely treat symptoms.

Research and clinical trials are being conducted using these substances, while state legislatures in more liberal enclaves are considering its legalization for medicinal purposes. Last year, Oregon became the first state to legalize its use for medical use. Investors are also starting to pay attention as there is significant commercial potential. 3 stocks that are working on developing treatments from psychedelics are ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD). 

ATAI Life Sciences N.V (ATAI)

ATAI is the latest psychedelic company to go public. It was able to raise $225 million at a $2.3 billion valuation, although shares are down by about 15% since opening. It has a variety of psychedelic-derived treatments that are in the clinical or research stage. The company has several impressive, high-profile investors with a track record of success like Peter Thiel, Mike Novogratz, and Apeiron Investment Group.

Currently, ATAI has 10 potential treatments in its pipeline, each in various stages of development. However, ATAI’s ambitions go beyond just developing treatments. The company sees itself as a drug development platform to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction, and other mental health conditions. Currently, it’s partnered with 14 companies on various joint ventures. 

This makes ATAI a way for investors to get exposure to a wide swathe of the industry as it’s more of a holding company rather than a drug development company. This structure has appeal to investors as its IPO was oversubscribed by 12 times. Further, private investors are getting increasingly excited about the space which bodes well for public companies. So far this year, VCs have invested $329 million in psychedelic startups, which is close to the $345 million that was raised in 2020. In 2018 and 2019, less than $100 million was raised each year.

Compass Pathways Plc (CMPS)

CMPS was founded in 2020 in London but has expanded to the US. The company is currently focused on using psilocybin to treat depression. Currently, this treatment is in PhaseIIb trials. Its earlier trials showed better outcomes for its treatments compared to a placebo.  

The company was also granted two new patents for an oral formulation of its synthetic psilocybin treatment. Given that it’s still in clinical trials, it’s not surprising that the company is not profitable with a net loss of $12.6 million in the first quarter. However, the company remains in a strong position with more than $300 million in cash. Additionally, its patents related to psilocybin have considerable value. 

The company expects that its clinical trials on its psilocybin-derived treatment will be completed by the end of the year. This will likely be the next catalyst for the stock price as the depression treatment market is estimated to be worth $13 billion, and many of today’s treatments have unpleasant side effects.

Mind Medicine Holdings (MNMD)

MNMD is based in New York and is developing psychedelic-based treatments to treat anxiety, addiction, and mental illness. Recently, the company announced a tie-up with Datavant, a health IT company to connect clinical trial data with external data. It also closed the acquisition of HealthMode, a machine learning, and digital therapeutics company. 

The company is working on treatments for a variety of different areas that are cumulatively worth $65 billion. Some of its most promising treatments are Project Lucy, its LSD experimental therapy, Project Flow for LSD microdosing, and Project Layla for opioid withdrawal. It also recently launched Project Angle which will investigate psychedelics for pain management. The company is also working on stripping these drugs of their hallucinogenic properties to isolate their medicinal use. 

Its last earnings report showed that MindMeld continues to augment its R&D pipeline as it conducts clinical trials and prepares therapeutic candidates for clinical trials. It reported a net loss of $14 million, but the company has considerable cash holding of $160 million. Further, it’s demonstrated the ability to raise cash through private placements and debt issuance. 

Conclusion

It’s still very early in this space as these companies still have to prove that psychedelic-derived treatments are safe and effective. However, they are attacking a big market and an area of major need as mental illness is becoming increasingly important especially with technology leading to increased isolation and anxiety among younger people.

Discover Today’s Best Growth Stocks

This article was written by Jaimini Desai, Chief Growth Strategist for StockNews.com.  Jaimini has been dialed into the hottest trends in investing:

  • Electric Vehicles
  • 5G
  • Internet of Things
  • Cloud Computing
  • Genomics
  • And Much More

If you would like to see more of his best growth stock ideas, then click the link below.

See Jaimini Desai’s Favorite Growth Stocks

 


ATAI shares were unchanged in premarket trading Friday. Year-to-date, ATAI has declined -6.99%, versus a 17.34% rise in the benchmark S&P 500 index during the same period.


About the Author: Jaimini Desai


Jaimini Desai has been a financial writer and reporter for nearly a decade. His goal is to help readers identify risks and opportunities in the markets. He is the Chief Growth Strategist for StockNews.com and the editor of the POWR Growth and POWR Stocks Under $10 newsletters. Learn more about Jaimini’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ATAIGet RatingGet RatingGet Rating
CMPSGet RatingGet RatingGet Rating
MNMDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

2 Warren Buffett Stocks to Buy and Never Sell

Warren Buffett’s long-term value investing strategy serves as a guide for investors to ensure high returns. With the market volatility becoming more severe after the Fed’s recent interest rate hike, Buffett’s top holdings could be ideal investments for long-term investors. To that end, buying and holding Johnson & Johnson (JNJ) and United Parcel Service (UPS) could be wise. Continue reading…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

:  |  News, Ratings, and Charts

The Most Sought-After Tech Stock to Buy Right Now

Shares of Microsoft (MSFT) have shed more than 25% year-to-date, with the rising interest rates causing a massive tech sell-off. However, the current low price level allows long-term investors to take a position in the stock to benefit from its solid growth prospects. The company has guided double-digit growth for fiscal 2023. Moreover, MSFT has been increasingly paying dividends, which should help generate a steady income stream. Read more…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

Read More Stories

More ATAI Life Sciences N.V. (ATAI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ATAI News